Treatment and outcomes of large vessel arteritis

Best Practice and Research: Clinical Rheumatology

Volumn 23, Issue 3, 2009, Pages 325-337

  Borg, Frances A ^a   Dasgupta, Bhaskar ^a  

^a SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

giant cell arteritis; immunosuppression; ischaemia; Takayasu's arteritis; visual loss

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; AZATHIOPRINE; CONTRAST MEDIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPYRIDAMOLE; ETANERCEPT; FLUORODEOXYGLUCOSE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABSENCE OF SIDE EFFECTS; ANGIOGRAPHY; AORTA ARCH SYNDROME; BLOOD VESSEL BIOPSY; BYPASS SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE COURSE; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHOGRAPHY; EYE DISEASE; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GIANT CELL ARTERITIS; HUMAN; HYPERTENSION; INFECTION; INFLAMMATION; ISCHEMIA; LOW DRUG DOSE; LUPUS LIKE SYNDROME; MONITORING; MORBIDITY; MORTALITY; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; REVASCULARIZATION; REVIEW; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT;

ANTI-INFLAMMATORY AGENTS; FEMALE; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; MALE; TAKAYASU ARTERITIS; TREATMENT OUTCOME; VISION DISORDERS;

EID: 66349118441     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2009.04.001     Document Type: Review

References (69)

1. Liu N.H., LaBree L.D., Feldon S.E., et al. The epidemiology of giant cell arteritis. Ophthalmology 108 (2001) 1145-1149
2. Kerr G.S., Hallahan C.W., Giordano J., et al. Takayasu arteritis. Ann Intern Med 120 (1994) 919-929
3. Vanoli M., Daina E., Salvarani C., et al. Takayasu's arteritis: a study of 104 Italian patients. Arthritis Rheum 53 1 (2005) 100-107
4. Park M.C., Lee S.W., Park Y.B., et al. Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol 34 (2005) 284-292
5. Maksimowicz-McKinnon K., Clark T.M., and Hoffmann G.S. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu Arteritis patients. Arthritis Rheum 56 3 (2007) 1000-1007
6. Subramanyan R., Joy J., and Balakrishnan K.G. Natural history of aortoarteritis (Takayasu's disease). Circulation 80 3 (1989) 429-437
7. Mwipatayi B.P., Jeffery P.C., Beningfield S.J., et al. Takayasu arteritis: clinical features and management: report of 272 cases. ANZ J Surg 75 (2005) 110-117
8. Ureten K., Ozturk M.A., Onat A.M., et al. Takayasu's arteritis: results of a university hospital of 45 patients in Turkey. Int J Cardiol 96 (2004) 259-264
9. Gonzalez-Gay M.A., Garcia-Porrua C., Llorca J., et al. Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine 79 5 (2000) 283-292
10. Salvarani C., Cimino L., Macchioni P., et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 53 2 (2005) 293-297
11. Loddenkemper T., Pankaj P., Katzan I., and Plant G.T. Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry 78 (2007) 1255-1259
12. Nesher G., Berkun Y., Mates M., et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine 83 (2004) 114-122
13. Galor A., and Lee M.S. Slowly progressive vision loss in giant cell arteritis. Arch Ophthal 124 (2006) 416-418
14. Danesh-Meyer H., Franzco, Savino P.J., et al. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 112 (2005) 1098-1103
15. Hayreh S.S., and Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 110 (2003) 1204-1215
16. Smetana G.W., and Shmerling R.H. Does this patient have temporal arteritis?. JAMA 287 1 (2002) 92-101
17. Makkuni D., Bharadwaj A., Wolfe K., et al. Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis?. Rheumatology 47 4 (2008) 488-490
18. Nuenninghoff D.M., Hunder G.G., Christianson T.J.H., et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis. Arthritis Rheum 48 12 (2003) 3522-3531
19. Shelhamer J.H., Volkman D.J., Parrillo J.E., et al. Takayasu's arteritis and its therapy. Ann Intern Med 103 (1985) 121-126
20. Boyev L.R., Miller N.R., and Green W.R. Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol 128 2 (1999) 211-215
21. Achkar A.A., Lie J.T., Hunder G.G., et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?. Ann Intern Med 120 12 (1994) 987-992
22. Ray-Chaudhuri N., Ah Kine D., Tijani S.O., et al. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol 86 (2002) 530-532
23. Narvaez J., Narvaez J.J., Nolla J.M., et al. Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology 44 (2005) 479-483
24. Bley T.A., Uhl M., Carew J., et al. Diagnostic value of high-resolution MR imaging in giant cell arteritis. AJNR Am J Neuroradiol 28 (2007) 1722-1727
25. Bley T.A., Markl M., Schlep M., et al. Mural inflammatory hyperenhancement in MRI of giant cell (temporal) arteritis resolves under corticosteroid treatment. Rheumatology 47 (2008) 65-67
26. Hata A., and Numano F. Magnetic resonance imaging of vascular changes in Takayasu arteritis. Int J Cardiol 52 (1995) 45-52
27. Tso E., Flamm S.D., White R.D., et al. Takayasu's arteritis. Utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 46 6 (2002) 1634-1642
28. 18FDG-PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging 31 5 (2004) 627-634
29. 18F]FDG-PET in the diagnosis of large vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 32 (2005) 674-681
30. Meller K., Grabbe E., Becker W., and Vosshenrich R. Value of F-18 FDG hybrid camera PET and MRI in early Takayasu aortitis. Eur Radiol 13 (2003) 400-405
31. Turlakow A., Yeung H.W.D., Pui J., et al. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med 161 (2001) 1003-1007
32. 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 55 1 (2006) 131-137
33. Schmidt W.A., Kraft H.E., Vorpahl, et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 337 19 (1997) 1337-1342
34. Karassa F.B., Matsagas M.I., Schmidt W.A., and Ioannidis J.P.A. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med 142 (2005) 359-369
35. Raninen R.O., Kupari M.M., Pamilo M.S., et al. Ultrasonography in the quantification of arterial involvement in Takayasu's arteritis. Scand J Rheumatol 29 (2000) 56-61
36. Park S.H., Chung J.W., Lee J.W., et al. Carotid artery involvement in Takayasu's arteritis. J Ultrasound Med 20 (2001) 371-378
37. Heyreh S.S., Zimmerman B., and Kardon R.H. Visual improvement with corticosteroid therapy in giant cell arteritis. Acta Ophthalmol Scand 80 (2002) 353-367
38. Proven A., Gabriel S.K., Orces C., et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 49 5 (2003) 703-708
39. Chan C.C.K., Paine M., and O'Day J. Steroid management in giant cell arteritis. Br J Ophthalmol 85 (2001) 1061-1064
40. Faroozan R., Deramo V.A., Buono L.M., et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 110 (2003) 539-542
41. Chevalet P., Barrier J.-H., Pottier P., et al. A randomized multi-center controlled trial using intravenous pulses if Methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year follow-up study of 164 patients. J Rheumatol 27 (2000) 1481-1491
42. Mazlumzadeh M., Hunder G.G., Easley K.A., et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids. Arthritis Rheum 54 10 (2006) 3310-3318
43. Jover J.A., Hernandez-Garcia C., Morado I.C., et al. Combined treatment of giant cell arteritis with methotrexate and prednisone. Ann Intern Med 134 (2001) 106-114
44. Hoffman G.S., Cid M.C., Helklmann D.B., et al. A multicentre randomized double blind placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46 5 (2002) 1309-1318
45. Mahr A.D., Jover J.A., Spiera R.F., et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56 8 (2007) 2789-2797
46. De Silva M., and Hazleman B.L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double blind study. Ann Rheum Dis 45 (1986) 136-138
47. Ozen S., Duzova A., Bakkaloglu A., et al. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr 150 1 (2007) 72-76
48. Hoffman G.S., Leavitt R.Y., Kerr G.S., et al. Treatment of glucocorticoid-resistant or relapsing Takayasu artertitis with methotrexate. Arthritis Rheum 37 4 (1994) 578-582
49. Valsakumar A.K., Chirammal Valappil U., Jorapor V., et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol 30 8 (2003) 1793-1798
50. Shinjo S.K., Pereira R.M.R., Tizziani V.A.P., et al. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol 26 (2007) 1871-1875
51. Daina E., Schieppati A., and Remuzzi G. Mycophenolate mofetil for the treatment of Takayasu arteritis. Ann Intern Med 130 (1999) 422-426
52. Hoffman G.S., Merkel P.A., Brasington R.D., et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu's arteritis. Arthritis Rheum 50 7 (2004) 2296-2304
53. Karageorgaki Z.T., Mavragni C.P., Papathanasiou M.A., et al. Infliximab in Takyasu arteritis: a safe alternative?. Clin Rheumatol 26 (2007) 984-987
54. Tato F., Rieger K., and Hoffmann U. Refractory Takayasu's arteritis successfully treated with the human monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol 24 3 (2005) 304-307
55. Cantini F., Niccoli L., Salvarani C., et al. Treatment of longstanding active giant cell arteritis with infliximab. Arthritis Rheum 44 12 (2001) 2933-2935
56. Andonopoulos A.P., Meimaris N., Daoussis D., et al. Experience with infliximab (anti-TNFα monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 62 (2003) 1116
57. Salvarani C., Macchioni P., Manzini C., et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica. Ann Intern Med 146 (2007) 631-639
58. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. Ann Intern Med 146 (2007) 621-630
59. Martinez-Taboada V.M., Rodriguez-Valverde V., Carreno L., et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis (2007) (epub 17 Dec 2007)
60. Bhatia A., Ell P.J., and Edwards J.C.W. Anti-CD20 monoclonal antibody (Rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 64 (2005) 1099-1100
61. Nesher G., Berkun Y., Mates M., et al. Low-dose aspirin and prevention of cranial ischaemic complications in giant cell arteritis. Arthritis Rheum 50 4 (2004) 1332-1337
62. Weaver F.A., Kumar S.R., Yellin A.E., et al. Renal revascularisation in Takayasu arteritis-induced renal artery stenosis. J Vasc Surg 39 (2004) 749-757
63. Fields C.E., Bower T.C., Cooper L.T., et al. Takayasu's arteritis: operative results and influence of disease activity. J Vasc Surg 43 (2006) 64-71
64. Park M.C., Lee S.W., Park Y.B., et al. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. Rheumatology 45 (2006) 600-605
65. Sharma B.K., Jain S., Bali H.K., et al. A follow-up study of balloon angioplasty and de-novo stenting in Takayasu arteritis. Int J Cardiol 75 (2000) S147-S152
66. Min P.-K., Park S., Jung J.-H., et al. Endovascular therapy combined with immunosuppressive treatment for occlusive arterial disease in patients with Takayasu's arteritis. J Endovasc Ther 12 (2005) 23-34
67. Miyata T., Sato O., Koyama H., et al. Long-term survival after surgical treatment of patients with Takayasu's arteritis. Circulation 108 (2003) 1474-1480
68. Brown M.M., Brown G.C., Sharma S., et al. Utility values associated with blindness in an adult population. Br J Ophthalmol 85 3 (2001) 327-331
69. Neunninghoff D.M., Hunder G.G., Christianson T.J.H., et al. Mortality of large-artery complications (aortic aneurysm, aortic dissection and/or large-artery stenosis) in patients with giant cell arteritis. Arthritis Rheum 48 12 (2003) 3532-3537